Eli Lilly & Co. (LLY) Tops Q4 EPS by 2c; offers outlook

Eli Lilly & Co. (NYSE: LLY) reported Q4 EPS of $5.32, $0.02 better than the analyst estimate of $5.30. Revenue for the quarter came in at $13.53 billion versus the consensus estimate of $13.78 billion.

GUIDANCE:

Eli Lilly & Co. sees FY2025 EPS of $22.50-$24.00, versus the consensus of $22.69. Eli Lilly & Co. sees FY2025 revenue of $58-61 billion, versus the consensus of $58.91 billion.

For earnings history and earnings-related data on Eli Lilly & Co. (LLY) click here.

You May Also Be Interested In

• OpenAI: after the Hugging Face incident, we committed to conducting a much broader review of actions taken by our models
• HeartSciences (HSCS) files $200M mixed shelf
• Bernstein sees downside risk to Apple's December quarter results